12/7/2025

Janusmed sex and gender

Janusmed sex and gender – semaglutide

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Semaglutide

Semaglutide

Class : C

Show all info

Print

Contact us

  1. Carlsson S, Andersson T, Jansson S, Nyström T, Rolandsson O, Wei Y. Increasing incidence of early-onset type 2 diabetes in Sweden 2006-2021. Eur J Public Health. 2025;:.

  2. Folkhälsomyndigheten. Övervikt och obesitas, interaktivt faktablad. Folkhälsomyndigheten [www]. [updated 2025-03-17, cited 2025-10-24].

  3. Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment. Curr Obes Rep. 2021;10(4):458-466.

  4. Censin JC, Peters SAE, Bovijn J, Ferreira T, Pulit SL, Mägi R et al. Causal relationships between obesity and the leading causes of death in women and men. PLoS Genet. 2019;15(10):e1008405.

  5. Statistikdatabas för operationer. Stockholm: Socialstyrelsen. 2024 [cited 2025-10-24.]

  6. Ozempic (semaglutide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-09-01, cited 2025-11-21].

  7. Wegovy Flex Touch (semaglutide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-09-01, cited 2025-11-21]

  8. Rybelsus (semaglutide). EPAR - Public assessment report. European Medicines Agency (EMA) [updated 2020-07-27, cited 2025-11-21]

  9. Petri KCC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes Obes Metab. 2018;20(9):2238-2245.

  10. Wegovy (semaglutide). EPAR - Public Assessment Report. European Medicines Agency (EMA) [updated 2022-03-10, cited 2025-11-21]

  11. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.

  12. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.

  13. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413.

  14. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.

  15. Verma S, Butler J, Borlaug BA, Davies M, Kitzman DW, Shah SJ et al. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024;84(9):773-785.

  16. Hamayal M, Akhtar CH, Ahmad N, Awwab M, Shahid W, Abbasi HS et al. Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis. Am J Cardiovasc Drugs. 2025;25(4):479-489.

  17. Leiter LA, Bain SC, Hramiak I, Jódar E, Madsbad S, Gondolf T et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73.

  18. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Carlsson S, Andersson T, Jansson S, Nyström T, Rolandsson O, Wei Y. Increasing incidence of early-onset type 2 diabetes in Sweden 2006-2021. Eur J Public Health. 2025;:.
  2. Folkhälsomyndigheten. Övervikt och obesitas, interaktivt faktablad. Folkhälsomyndigheten [www]. [updated 2025-03-17, cited 2025-10-24].
  3. Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment. Curr Obes Rep. 2021;10(4):458-466.
  4. Censin JC, Peters SAE, Bovijn J, Ferreira T, Pulit SL, Mägi R et al. Causal relationships between obesity and the leading causes of death in women and men. PLoS Genet. 2019;15(10):e1008405.
  5. Statistikdatabas för operationer. Stockholm: Socialstyrelsen. 2024 [cited 2025-10-24.]
  6. Ozempic (semaglutide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-09-01, cited 2025-11-21].
  7. Wegovy Flex Touch (semaglutide). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-09-01, cited 2025-11-21]
  8. Rybelsus (semaglutide). EPAR - Public assessment report. European Medicines Agency (EMA) [updated 2020-07-27, cited 2025-11-21]
  9. Petri KCC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes Obes Metab. 2018;20(9):2238-2245.
  10. Wegovy (semaglutide). EPAR - Public Assessment Report. European Medicines Agency (EMA) [updated 2022-03-10, cited 2025-11-21]
  11. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
  12. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
  13. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413.
  14. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
  15. Verma S, Butler J, Borlaug BA, Davies M, Kitzman DW, Shah SJ et al. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024;84(9):773-785.
  16. Hamayal M, Akhtar CH, Ahmad N, Awwab M, Shahid W, Abbasi HS et al. Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis. Am J Cardiovasc Drugs. 2025;25(4):479-489.
  17. Leiter LA, Bain SC, Hramiak I, Jódar E, Madsbad S, Gondolf T et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73.
  18. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]